Q2 sales up 2.4% but profit falls on rising costs; thesis unchanged

What happened

Stran & Company reported Q2 2026 sales of $33.36 million, a 2.4% increase year over year, but EPS declined due to rising costs and weaker quarterly profit. The modest revenue growth failed to translate into improved profitability, consistent with the company's FY2025 pattern of gross margin pressure from the lower-margin SLS segment. The earnings release does not detail operating cash flow or unearned revenue, but the profit decline suggests working capital and cost pressures persist, key risks highlighted in the prior deep-value analysis. This result reinforces the WAIT rating, as the company has not yet demonstrated the cash conversion or margin stabilization needed to justify a higher valuation. Investors should continue to monitor the next quarterly filing for signs of operating cash flow improvement and rewards program ramp before reassessing.

Implication

This quarter's results show that revenue growth alone is insufficient to drive shareholder value, as rising costs erode profitability. The lack of detail on cash flow metrics means the core concerns from the prior analysis—negative operating cash flow and unearned revenue decline—remain unresolved. Until there is evidence of cost control, higher-margin program growth, and improved cash conversion, the stock is unlikely to re-rate upward. Investors should wait for at least one or two quarterly reports showing positive operating cash flow and stable gross margins before considering entry. The current price does not offer sufficient margin of safety given the execution risks.

Thesis delta

The WAIT thesis remains intact, but this earnings report adds weight to the bear scenario. Revenue growth of 2.4% with declining EPS indicates gross margin pressure and rising operating costs are not yet resolved. The next two quarterly filings must show operating cash flow improvement and unearned revenue growth to shift the thesis to positive.